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Abstract
Background: Entecavir (ETV) is a deoxyguanosine analog competitive inhibitor of hepatitis B virus (HBV) polymerase that
exhibits delayed chain termination of HBV DNA. A high barrier to entecavir-resistance (ETVr) is observed clinically, likely due
to its potency and a requirement for multiple resistance changes to overcome suppression. Changes in the HBV polymerase
reverse-transcriptase (RT) domain involve lamivudine-resistance (LVDr) substitutions in the conserved YMDD motif (M204V/I
6 L180M), plus an additional ETV-specific change at residues T184, S202 or M250. These substitutions surround the putative
dNTP binding site or primer grip regions of the HBV RT.
Methods/Principal Findings: To determine the mechanistic basis for ETVr, wildtype, lamivudine-resistant (M204V, L180M)
and ETVr HBVs were studied using in vitro RT enzyme and cell culture assays, as well as molecular modeling. Resistance
substitutions significantly reduced ETV incorporation and chain termination in HBV DNA and increased the ETV-TP inhibition
constant (Ki) for HBV RT. Resistant HBVs exhibited impaired replication in culture and reduced enzyme activity (kcat) in vitro.
Molecular modeling of the HBV RT suggested that ETVr residue T184 was adjacent to and stabilized S202 within the LVDr
YMDD loop. ETVr arose through steric changes at T184 or S202 or by disruption of hydrogen-bonding between the two,
both of which repositioned the loop and reduced the ETV-triphosphate (ETV-TP) binding pocket. In contrast to T184 and
S202 changes, ETVr at primer grip residue M250 was observed during RNA-directed DNA synthesis only. Experimentally,
M250 changes also impacted the dNTP-binding site. Modeling suggested a novel mechanism for M250 resistance, whereby
repositioning of the primer-template component of the dNTP-binding site shifted the ETV-TP binding pocket. No structural
data are available to confirm the HBV RT modeling, however, results were consistent with phenotypic analysis of
comprehensive substitutions of each ETVr position.
Conclusions: Altogether, ETVr occurred through exclusion of ETV-TP from the dNTP-binding site, through different, novel
mechanisms that involved lamivudine-resistance, ETV-specific substitutions, and the primer-template.
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Introduction
Approximately 350 million people worldwide are chronically
infected with hepatitis B virus (HBV) [1]. HBV is the most
prevalent chronic liver infection, often leading to cirrhosis, liver
failure and primary hepatocellular carcinoma [reviewed in [2]]
and responsible for nearly one million deaths per year [1].
Treatments for chronic HBV include parenteral regimens
containing the immunomodulator interferon a or oral nucleo-
side/nucleotide analogue reverse transcriptase inhibitors (NRTI)
which target the reverse transcriptase (RT) activity of the HBV
polymerase, the only enzymatic target of the virus. Five NRTIs
are approved for treating chronic HBV in the U.S., including
lamivudine (LVD), the phosphonate adefovir, administered as a
dipivoxil prodrug, telbivudine, the phosphonate tenofovir, admin-
istered as a disoproxil fumarate prodrug, and entecavir (ETV).
The NRTI inhibitors approved for HBV therapy can be described
structurally as having L-configuration ribose isosteres of LVD and
telbivudine, alkyl chain ribose isosteres of adefovir and tenofovir, or,
in the caseof ETV, a D-configuration cyclopentyl riboseisostere with
an exocyclic alkene replacing the ribose furanose oxygen. We
previously reported that the novel structure of ETV can be modeled
into a unique hydrophobic pocket within the HBV RT dNTP
bindingsite, consistentwiththe observed potencyofETVandactivity
against HBV with resistance substitutions to either the L-nucleoside
analogs or alkyl chain phosphonates [3]. ETV HBV DNA chain
terminationwasalsofoundtooccurbya novelmechanism[3,4].The
prior modeling studies also revealed the basis for partial cross-
resistance of LVDr HBV to ETV since the pocket accessed by ETV
was partly reduced in HBV with LVDr substitutions of the tyrosine-
methionine-aspartate-aspartate (YMDD) dNTP-binding active site
loop of the polymerase [3].
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clinical study patients with LVDr HBV that acquired additional
substitutions and exhibited virologic breakthrough during ETV
therapy [5]. Both patients were infected with HBV with
M204V+L180M LVDr substitutions at study entry and developed
additional substitutions T184G & S202I, or M250V on therapy.
Breakthrough isolates displayed high levels of phenotypic resis-
tance to ETV in vitro. The T184, S202 or M250 ETV signature
substitutions did not display significant resistance in the absence of
LVDr changes, establishing that multiple substitutions were
required for phenotypic resistance leading to virologic break-
through on ETV. Resistance studies of patients treated for up to 5
years with ETV have shown that ETV-resistance (ETVr) is rare
(,1% over 5 Years) in nucleoside naive patients, consistent with a
high barrier to resistance [6]. Resistance occurs more frequently in
ETV patients with LVDr HBV, due to the requirement for only
one additional substitution at T184, S202 or M250 for high level
ETVr. However, different ETVr substitutions result in various
levels of phenotypic ETVr [7,8]. In addition, ETVr substitutions
in isolates with only the M204I substituted LVDr HBV and not
the M204V+L180M LVDr virus, phenotypic resistance to ETV is
diminished.
In this report we use cell culture, in vitro enzyme and molecular
modeling studies to characterize the mechanism(s) for phenotypic
ETVr in HBV with signature ETVr substitutions at T184, S202 or
M250 in LVDr HBV. The results show that ETVr substitutions in
LVDr HBV cause further restriction of the ETV-triphosphate
(ETV-TP) binding pocket, through steric influences but also by
disrupting stabilizing interactions of the active site YMDD loop. In
addition, ETVr substitutions in the primer grip region of HBV RT
appear to operate through an additional novel mechanism as
revealed by template-dependent phenotypic changes and effects
on activity through the nucleotide-binding pocket. The results also
suggest the basis for a lack of ETVr in HBV lacking LVDr
substitutions.
Results
ETV Resistance (ETVr)
HBV containing LVDr substitutions M204V+L180M exhibit
reduced ETV susceptibility that can lead to virologic breakthrough
with additional substitutions at ETVr signature residues T184,
S202 or M250 [5,8]. The levels of ETVr observed in cell culture
and in vitro enzymatic assays of representative clones with ETVr
substitutions are shown in Table 1. ETV and ETV-TP displayed
potent inhibition of wildtype HBV in culture and HBV
polymerase RT in vitro with EC50 and IC50 values of 3 and
0.5 nM, respectively. LVDr HBV shows approximately 8-fold
cross-resistance to ETV in culture [3,7], despite higher fold
changes for LVDr HBV RT in vitro, likely a result of efficient
intracellular phosphorylation to the triphosphate at nanomolar
exposures [9]. High levels of ETVr were observed when HBV
clones contained ETVr signature substitutions in a LVDr
background both in vitro (.400-fold) and in culture (.200-fold),
respectively (Table 1). A full analysis of the different ETVr
substitutions in culture has been reported for engineered [8] and
clinical [7] ETVr HBV isolates. A previously described isolate
containing both T184G and S202I substitutions [5] displayed the
highest ETVr levels, suggesting that multiple ETVr changes in a
LVDr background may have additive or synergistic effects.
Resistance was specific for ETV-TP as the IC50 values for the
same ETVr isolates against 29,39-dideoxyguanosine-59-triphos-
phate (ddGTP), a known competitive inhibitor of HBV RT, all fall
within a similar range of approximately two-fold above back-
ground (Table 1). The cross-resistance profile for these ETVr
substitutions has been shown to be relatively restricted in cell
culture, as ETVr HBV does not show reduced susceptibility to
adefovir [5,10] or tenofovir [11].
Kinetic Studies
To explore the mechanism(s) underlying ETVr, we compared
enzymatic parameters for the wildtype and resistant enzymes.
Detailed kinetic studies for the HBV polymerase were not possible
due to the limitations of studying nucleocapsid-associated enzyme
covalently linked to its minus strand DNA template. Nevertheless,
important mechanistic information was gained. The recognition
for the natural dGTP substrate was only modestly affected by
ETVr changes, which increased Km values 2.2- to 2.6-fold
(Table 2). The only exception was the most resistant, quadruple-
substituted RT with ETVr T184G+S202I changes in a
M204V+L180M LVDr background, where the apparent Km for
dGTP was approximately 7-fold less than that for wildtype. The
calculated Ki/Km ratios revealed that the wildtype HBV RT
preferred ETV-TP over dGTP [Ki/Km ratio ,1], as previously
reported [4,9]. The LVDr HBV polymerase showed a modest
(30-fold) alteration in the Ki for ETV-TP relative to the striking
Table 1. Phenotypic ETV Resistance of HBV Clones.
Cell Culture In Vitro Polymerase In Vitro Polymerase
ETV EC50, nM,
Average 6 SD (Range)
a
ETV-TP IC50, nM,
Average 6 SD (Range)
a
ddGTP IC50, nM,
Average 6 SD (Range)
a
Wildtype
b 3.061.5 (1.4–5.2) 0.560.1 (0.4–0.7) 87.668.4 (78.0–92.9)
LVDr L180M + M204V
c 30.4621.6 (10.4–58.6) 27.165.6 (20.9–31.9) 137.9610.0 (123.5–148.3)
LVDr + T184L
d 738.46119.4 (654.0–822.8) 372.96142.7 (236.4–542.8) ND
LVDr + S202G
d 1,207.361,051.6 (463.7–1,950.9) 258.3625.5 (222.7–290.8) 125.168.8 (120.0–135.2)
LVDr + M250V
d 3,083.661,795.8 (1,813.7–4,353.4) 229.0649.5 (192–323.9) 153.7651.4 (117.3–190.0)
LVDr + T184G + S202I
e .4,000 (.4,000) 636.1619 (617.2–655.2) 187.666.7 (180.0–192.7)
aEC50 and IC50 values represent the mean 6 standard deviation (SD) from at least 3 independent experiments.
bWildtype values from a single isolate tested in parallel [5], the average ETV EC50 for a panel of 76 wildtype isolates =3.462.0 nM.
cLVDr values from a single isolate tested in parallel [5], the average ETV EC50 for a panel of 15 LVDr isolates =31.1617.5 nM.
dValues averaged from 2 independent isolates.
eValues obtained from a single patient isolate [5].
doi:10.1371/journal.pone.0009195.t001
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The resulting high Ki/dGTP Km ratios for the ETVr enzymes
suggested preferential recognition of dGTP relative to ETV-TP,
more than 600-fold changed from the wildtype.
In agreement with other reports, HBV with LVDr substitutions
exhibited impaired HBV replication in culture [12,13,14]. HBV
isolates with ETVr substitutions were also shown to be replication
impaired in culture [5,8]. To determine if ETVr substitutions also
negatively affected HBV polymerase catalytic efficiency, we
determined the estimated kcat or turnover number as a measure
of the number of reaction complexes that could be converted to
product, per molecule of enzyme per unit of time. As illustrated in
Table 2, all resistant polymerases displayed reductions in
enzymatic activity relative to the wildtype, with the ETVr
quadruple mutant showing the greatest reduction (3.7-fold less
than the wildtype). The reduced polymerase activity of the ETVr
enzymes is consistent with reduced replication of the resistant
viruses in culture.
ETVr HBV Incorporate Reduced Levels of ETV
The experiments above suggest ETVr substitutions reduce the
recognition of ETV-TP by HBV polymerase. Since the proposed
mechanism of activity for ETV involves addition to the growing
HBV DNA followed by chain termination [3], HBV RTs with
ETVr should less efficiently recognize and incorporate ETV. To
test this, we determined the level of [
3H]-ETV incorporated into
the DNA of various HBVs in culture (Figure 1), relative to the total
HBV DNA synthesized. To control for different levels of DNA
produced by the various HBVs, the levels of HBV DNA in the
nucleocapsid preparations were quantified according to HBV real-
time PCR performed on the samples (Fig. 1), or [
3H]-thymidine
incorporation in a parallel sample (not shown). Scintillation
counting and standardization revealed that ETVr HBV contained
a lower percentage of the total nucleocapsid DNA radiolabeled
with [
3H]-ETV than the wildtype (Figure 1). LVDr HBV had an
average of 9% [
3H]-ETV radiolabeled DNA relative to the
wildtype while the ETVr substitutions resulted in average levels
from 1.2 to 4% of wildtype (Fig. 1). These results extend the kinetic
studies by showing that the reduced recognition of ETV by ETVr
RT was accompanied by reduced incorporation, and presumably,
chain termination.
HBV polymerase has been shown to be capable of exonucleo-
lytically proofreading chain terminating nucleotides from the 39
end of DNA through pyrophosphorolysis [15]. While the results in
Figure 1 do not exclude this mechanism of resistance, non-obligate
chain terminating NRTIs such as ETV have been found to be
resistant to pyrophosphorolysis [16] because DNA chain termina-
tion occurs 1 to 3 bases after the NRTI is incorporated. We have
been unable to demonstrate removal of ETV incorporated into
HBV DNA using pyrophosphorolysis with either wildtype or
ETVr enzymes (data not shown). The inability of ETV to be
proofread by HIV RT has been reported by Tchesnokov et al.
[17].
Molecular Modeling
A previously described molecular model [3] was used to further
explore the impact of the ETVr changes on the HBV RT. Studies
using this homology model of HBV-RT/DNA/dGTP complex
based on the HIV-1 RT/DNA structure revealed that the
exocyclic alkene of ETV-TP fit into a hydrophobic pocket at the
Table 2. Kinetic Parameters for HBV Polymerases.
dGTP Km,n M
a (Fold WT)
b Ki, nM (Fold WT) Ki/Km (Fold WT) kcat,m i n
21 (Fold WT)
Wildtype (WT) 5.060.5 (1) 0.4 (1) 0.08 (1) 0.24 (1)
LVDr M204V+L180M 3.560.4 (14) 12.3 (30.8) 3.5 (43.8) 0.093 (2.58)
LVDr + T184L 1.960.6 (2.6) 224.5 (561.3) 118.2 (1477.5) 0.13 (1.85)
LVDr + S202G 2.160.1 (2.4) 146.7 (366.8) 69.9 (873.8) 0.11 (2.18)
LVDr + M250V 2.360.5 (2.2) 121.2 (303.0) 52.7 (658.8) 0.17 (1.41)
LVDr + T184G + S202I 0.760.1 (7.1) 155.1 (387.8) 221.6 (2770.0) 0.076 (3.16)
aValues are the mean 6 standard deviation from at least three independent experiments.
bFold change from wildtype value.
doi:10.1371/journal.pone.0009195.t002
Figure 1. Incorporation of [
3H]-ETV into HBV nucleocapsid
DNA in culture. [
3H]-ETV was added to cultures of HepG2 cells
transfected with an HBV expression construct, as detailed under
Materials and Methods. HBV nucleocapsids were isolated from cell
lysates, as detailed under Materials and Methods, and radiolabeled HBV
DNA was quantified through scintillation counting. The levels of
nucleocapsid-associated [
3H] from cells grown in [
3H]-ETV are presented
as percent wildtype control values 6 standard deviation. Yields of HBV
nucleocapsid DNA were standardized according to real-time PCR
quantification of HBV DNA within isolated nucleocapsids, as detailed
under Materials and Methods. Similar results were obtained by
standardizing total HBV nucleocapsid DNA levels with nucleocapsids
from parallel cultures metabolically labeled with [
3H]-thymidine (data
not shown). WT, wildtype nucleocapsids; LVDr, M204V+L180M substi-
tuted HBV nucleocapsids, LVDr+M250V, M204V+L180M+M250V substi-
tuted nucleocapsids; LVDr+T184G+S202I, M204V+L180M+T184G+S202I
substituted nucleocapsids. HBVs were tested independently 3 to 4
times, except the LVDr+M250V, which was tested twice.
doi:10.1371/journal.pone.0009195.g001
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M204V+L180M reduced the size of this pocket to exclude the
binding of LVD-TP with its larger oxathiolane ring [18] but not
the binding of ETV-TP [3]. The ETV binding pocket of LVDr
HBV (M204V+L180M) is shown in Figure 2A. Several different
ETVr substitutions have been observed in ETV-treated patients,
including T184A/C/F/G/I/L/M/S, S202C/G/I, and M250 I/
L/V. Cell culture phenotypic analysis has revealed that not all of
these substitutions result in significant reductions in ETV
phenotypic susceptibility [8].
T184 and S202 Substitutions
Introduction of the ETVr signature substitutions into LVDr
HBV RT caused further reduction of the size of the ETV-binding
pocket to sterically impede ETV-TP binding, in agreement with
the experimental findings above. Figure 2B shows that introduc-
tion of the S202G substitution causes repositioning of the L180M
and M204V residues to further restrict the ETV-TP binding site.
T184 substitutions caused similar changes to the LVDr HBV RT
(not shown).
Interaction of T184 and S202 Residues
The LVDr substitutions M204V and L180M lie juxtaposed in
the HBV RT dNTP binding pocket, the M204 positioned within
the YMDD active site loop and the L180 residue in the adjacent
alpha helix. Interactions between these structural motifs were first
proposed upon the double substitution M204V+L180M encoding
LVDr [18]. The S202 residue is also located on the YMDD active
site loop of the HBV RT, juxtaposed to the T184 residue on the
adjacent alpha helix. It is therefore interesting that substitutions at
T184 and S202 residues in LVDr HBV can result in ETVr. In the
HBV RT model, T184 forms a hydrogen bond with the side-chain
hydroxyl group of S202, which in turn hydrogen bonds with the
backbone carbonyl of residue 204 (204 valine in Figure 3). This
hydrogen bonding network stabilizes the YMDD loop to optimally
anchor the incoming dNTP and the 39 nucleotide of the growing
DNA strand for the SN2 addition reaction. In addition, the
hydrogen bonding network holds the small pocket at the back of
the dNTP binding site open. The S202G, C or S202I substitutions
lose the ability to hydrogen bond with T184 and M204. The
smaller, more flexible S202G substitution destabilizes the YMDD
loop and closes the ETV binding pocket in the back of the dNTP
site (Fig. 2B). The S202I change sterically closes the pocket as this
region of the loop moves to accommodate the larger side chain.
The results of comprehensive phenotypic analysis of substitutions
at positions S202 [8] indicated that S202A/G/C/T/V/N
replicated well and S202 I/F/Y replicated poorly, but that other
S202 changes did not replicate. Additionally, large substitutions
S202F/I/Y and small substitutions S202G/A were highly resis-
tant. These results are consistent with the model in that highly
tolerated substitutions were uncharged, similar to serine in size,
while resistant residues could be either large or small, which
repositioned the YMDD loop closer or further from the stabilizing
alpha-helix containing L180M, and could further impact the
YMDD loop changes on the ETV-TP binding-pocket. Substitu-
tions of larger and charged groups did not grow well [8]. This is
likely due to a misfolding or positioning the YMDD loop into the
dNTP-binding site. Residues similar in size to the serine grow well
Figure 2. Molecular homology model of resistant HBV RTs. The ETV-TP binding pocket of HBV RT. [3]. (A) HBV RT with LVDr substitutions,
M204V+L180M, (B) HBV RT with LVDr + S202G. HBV RT, ETV-TP and primer-template DNAs are labeled. The residues lining the pocket are orange,
changes from LVDr are red, from ETVr are blue, and the M250, S202, and T184 residue positions (panel B) are pink. Panel A was essential reproduced
from [3] with permission.
doi:10.1371/journal.pone.0009195.g002
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residues (G,A) were highly resistant.[8]
The T184 substitutions can also be divided into two functional
types. The smaller T184G substitution (relative to threonine)
allows the YMDD loop to be more flexible which dynamically
closes the ETV binding pocket. T184 A and S changes also fit this
model. The larger substitution T184L forces the ETV binding
pocket closed as the YMDD loop is repositioned to accommodate
the larger amino acid. T184 I, M, F, substitutions also fit this
pattern. Therefore ETVr substitutions at T184 or S202 can cause
resistance to ETV through steric repositioning of the YMDD loop
and shrinking the ETV-TP binding pocket, or by disrupting the
H-bonding network that stabilized the active site conformation.
The T184G substitution [5] was also modeled into the LVDr
HBV RT and produced a similar change in the ETV-binding
pocket as the S202G change in Figure 2 (not shown). The results of
comprehensive analysis of changes at T184 [8] were explained by
the modeling; only charged residues did not grow well[8]. Among
those that grew well, both large (T184L/M/F/Q/N) and small
(T184A/G/C) residues resulted in ETVr.
M250 Substitutions
Substitutions at residue M250 within LVDr HBV that result in
ETVr are less straightforward to interpret and suggest resistance
may be imparted by changes in both the dNTP binding site and in
the position of the growing DNA chain. In our model, the M250
residue lies in the primer grip region of the HBV RT [18] and the
methionine side chain packs against Y203 of the YMDD loop, the
dNMP at the +2 position of the primer DNA strand, and L66
(Figure 4). In our previous study [3] it was proposed that ETV
chain termination resulted from steric contact between ETV and
Y203 and L66. Therefore, substitution of M250 with a shorter,
branched valine or leucine could mitigate HBV DNA chain
termination of ETV adduct by providing room for Y203 and L66
to move out of the way as ETV moves through the +1, +2, and +3
position. However, the lack of increased [
3H]-ETV incorporation
into HBV DNA (Figure 1) does not support readthrough as a
resistance mechanism. Alternatively, in the model of M250V, the
valine side chain packs tightly against the dNMP at the +2 position
and produces a small hole between M250V/L and Y203 and L66.
Amino acid residues K60-L66 pack against the RNA or DNA
ribose backbone of the template strand and N65 simultaneously
hydrogen bonds with two adjacent 29-hydroxyl groups when the
template strand is RNA. In response to the M250 mutation, the
Figure 4. Position of residue M250 in the HBV RT/DNA
molecular model. A) The relative location of the M250, Y203,
M204V, and other resistance residues are shown with primer-template
DNA and ETV-TP in the dNTP binding site. The proximity of the M250
residue to both primer DNA and the Y203 residue are shown, indicating
possible mechanisms for effects of M250 substitutions on the dNTP
binding site, as well as the influence different side chains could have on
primer positioning. B) M250 is packed against L66 and N65 forms
hydrogen bonds (white dotted lines) to the hydroxyl groups on the
backbone of the RNA template strand. C) The smaller side chain of the
M250V no longer packs against L66. As indicated by the arrows
(protein:green; DNA:gray; M250V:purple), the resulting conformational
change in the protein to close the resultant hole repositions the RNA/
DNA slightly over the NTP binding site. The slight modification to the
NTP site enhances LVD binding while decreasing the binding affinity of
ETV.
doi:10.1371/journal.pone.0009195.g004
Figure 3. The T184-S202-204 hydrogen bonding network
stabilizes the YMDD loop. The YMDD loop is shown with residues
M204V+L180M and the H-bonding between residues T184, S202 and
M204V are shown as dotted white lines.
doi:10.1371/journal.pone.0009195.g003
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compression between M250V and the +2 dNMP and L66/N65
as they move to fill the hole between M250V and Y203 and L66.
This slightly repositions the primer strand over the ETV-TP/
LVD-TP binding pocket, subtly changing the shape of the pocket
within the dNTP binding site. This results in an increase in the size
of the pocket near M204V and shrinking of the corner of the
pocket comprised by the dNMP in the +1 position of the template
strand. The pivoting of the nucleic acid duplex is amplified due to
the additional 29-hydroxyl groups on the template strand of the
DNA/RNA complex. Comprehensive phenotypic analysis of
M250 substitutions in LVDr HBV [8] provided support for the
model: Again charged residues did not grow well[8]. This is
consistent with the hydrophobic packing of M250 against L66
(Figure 4). M250 substitutions that were smaller than methionine
and replicated well, M250A/G/S/T/C/D/E/Q/N/V/L/I, were
all resistant. Those that were large, replicated and could maintain
the positioning of the primer:template, M250F/Y, retained ETV
susceptibility. In the model, the M250 substitutions F and Y
provided edge to face stacking with Y203 and packed against L66.
Altogether, these results are consistent with the model that the
primer-grip positioning of the primer template modified the ETV-
TP pocket.
Experimental Evidence for the Mechanism of
M250-Dependent Resistance
Experimental results suggest M250 changes affect the dNTP
binding pocket. The M250V substituted HBV RT in the absence
of LVDr changes was constructed and tested for susceptibility to
LVD, an obligate chain terminator which should not be impacted
by the mechanism that could potentially affect ETV chain
termination. Replication of the singly M250V substituted HBV
was 7-fold hypersensitive to LVD in culture (wildtype HBV LVD
EC50=794 nM, M250V HBV LVD EC50=116 nM), suggesting
the M250 changes affected the dNTP binding site and not just
elongation of the growing DNA.
Another set of experiments showed that the M250 substitutions
in LVDr HBV decreased ETV susceptibility in a template-
dependent manner. ETV inhibits HBV polymerase synthesis of
DNA in vitro during both RNA-directed first (minus) strand
synthesis as well as DNA-directed second (plus) strand synthesis
[4]. To determine if ETVr was influenced by the template for
DNA synthesis, cell culture EC50 determinations were made using
strand-specific riboprobes to hybridize to the synthesized HBV
DNA, in parallel with the typical double-stranded DNA probe. In
this way an ETV EC50 for each strand of DNA synthesis during
the HBV cell culture was determined. The EC50 determinations
using the strand-specific DNA hybridization showed that HBV
nucleocapsids containing wildtype, LVDr substituted and LVDr +
T184 or S202 substitutions displayed nearly equivalent levels of
susceptibility (EC50) in synthesis of both stands of HBV DNA
(Figure 5, compare each strand probe to the results using the
double-stranded DNA probe). In contrast, ETVr due to
substitutions of M250V or M250L in LVDr HBV was found to
be manifested primarily during RNA-directed minus strand DNA
synthesis, as the EC50 for the first (minus) strand was increased
relative to that for the second (plus) strand. The minus strand EC50
was similar to the EC50 obtained using the double-stranded DNA
probe. These observations are consistent with M250 changes in
the primer-grip region of HBV RT influencing ETVr at least in
part through the template for DNA synthesis. An independent
observation supported this hypothesis; resistance was seen using
nucleocapsids prepared in our typical manner (Materials &
Methods), isolated from cells grown in PFA to inhibit minus
strand synthesis, enhancing the in vitro minus-strand synthesis
activity of the preparations [19]. If experiments were performed
using nucleocapsids from cultures without PFA, or if enzyme
reactions were extended from the standard 1 hour to 3 hours in
Figure 5. Analysis of ETVr through strand-specific DNA synthesis in culture. Cell culture ETV EC50 determinations were made for wildtype
and various resistant HBVs. The levels of HBV DNA synthesized in the presence of ETV was determined by HBV-specific probe hybridization to HBV
nucleocapsid DNA from the cultures. The probes used were the typical double-stranded DNA probe, or strand-specific riboprobes which hybridized
to a single HBV DNA strand. Comparison of strand-specific EC50 versus double stranded EC50 for wildtype polymerase (WT) or LVDr M204V+L180M
HBV, or the LVDr substitutions with ETVr substitutions (+T184, +S202, +M250) as indicated. Values at 4000 nM indicate that 50% inhibition was not
observed at the highest ETV concentration tested.
doi:10.1371/journal.pone.0009195.g005
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the cell culture resistance to ETV of the LVDr+M250V virus was
not observed enzymatically in vitro (data not shown). In contrast,
substitutions at T184 or S202 in LVDr HBV resulted in ETVr
under all these conditions. Thus, only M250 ETVr substitutions
displayed template dependence.
Discussion
The emergence of resistance is an intrinsic challenge with
antiviral therapy. The nature and mechanisms of resistance for
each therapy are important to develop treatment strategies,
including for patients already harboring resistant viruses. Resis-
tance to LVD can arise from a single substitution at residue M204
in the YMDD active site loop of HBV polymerase (with or without
a compensatory change at L180) and results in high-level
phenotypic resistance and clinical failure [20,21,22]. This YMDD
substitution reduces the size of the LVD binding pocket, also
causing complete cross resistance to other L-configuration ribose
NRTIs such as telbivudine and emtricitabine [5,10,18,23]. A
similar profile is observed with YMDD changes in HIV RT
[24,25,26,27]. In contrast, resistance to adefovir leading to
virologic breakthrough can arise from either A181 V or T
substitutions [28], or N236T [29]. Modeling studies suggest that
the N236T change may indirectly affect binding of the terminal c-
phosphate of adefovir-diphosphate [30,31] and changes at A181 of
the alpha helix adjacent to the YMDD active site loop likely affect
the position of the YMDD loop itself or the nucleotide in the +1
position through interactions of A181V or T with the M204 S-
methyl moiety of the YMDD loop [3]. A181 changes also impart
LVDr [31,32,33].
The resistance pattern emerging from clinical studies of ETV
suggest a more complex scenario; multiple changes in the HBV
RT are required for clinically meaningful resistance, substitutions
at T184, S202 or M250 in the HBV RT must be accompanied by
LVDr substitutions M204V/I 6 L180M [10]. However, high level
phenotypic resistance does not occur when ETVr substitutions are
present with only the M204I LVDr substitution [7] and does not
result in virologic breakthrough [6].
In the present study, cell culture, in vitro enzyme, and molecular
modeling approaches were used to show that the mechanism for
ETVr involved decreased recognition and binding of ETV-TP by
the resistant HBV polymerase. While ETV-TP accesses the same
binding pocket in the HBV RT as LVD-TP, the exocyclic alkene
group of the ETV-TP ribose isostere is small enough that binding
is retained with LVDr changes while the larger oxathiolane moiety
of LVD-TP can no longer be accommodated [3]. Further changes
at positions T184, S202 or M250 in LVDr HBV, however,
prevent ETV-TP binding. These ETVr signature substitutions in
LVDr HBV RT resulted in substantial increases in ETV-TP Ki
values. However, the majority of the ETVr RTs showed only a
modest decrease in apparent Km values for natural dGTP.
Consistent with this finding was the observation that little cross
resistance was observed between the ETVr RTs and dideoxy-
GTP. These results suggest that recognition of natural nucleotides
was not markedly altered by the ETVr RT changes, similar to
LVDr YMDD changes in HBV [18,34] and HIV RTs [24].
Decreased recognition and utilization of ETV-TP by the
resistant enzymes resulted in reduced intracellular incorporation
of [
3H]ETV-MP into HBV nucleocapsid DNA inside cells. Since
the proposed mechanism for ETV activity involves incorporation
into the growing DNA chain followed by chain termination a few
bases downstream, these results highlight the ultimate effect of
ETVr. The fact that phenotypic resistance to ETV was observed
in both culture and in vitro RT assays confirmed that the
mechanism did not involve intracellular phosphorylation and
was localized to the HBV RT activity.
Similar to LVDr HBV substitutions in the dNTP-binding
pocket [12,13,14], ETVr changes were accompanied by replica-
tion defects to approximately 40-60% of the wild-type, similar to
LVDr HBV [5] [8]. Here the catalytic efficiency of the ETVr
polymerases was also reduced relative to the wildtype, confirming
and providing a basis for the impaired HBV replication observed.
The turnover number (kcat) of the ETVr polymerases were all
approximately 2–3 fold lower than wildtype with the most resistant
polymerase harboring the most ETVr substitutions having the
lowest value. Despite these modest changes, they are consistent
with the observations from cell culture studies. Although ETVr
could presumably also involve enhanced replication through
adaptive changes, the fact that resistance was observed through
reduced ETV utilization and that resistant HBV and polymerase
did not have enhanced replicative capacity, argue against the
adaptive mechanism for resistance.
HIV resistance to LVD results from discrimination of
incorporation of LVD-TP (exclusion) by steric hindrance (re-
viewed by Sarafianos et. al.[35]). Recent realization that ETV
displays weak activity against HIV RT has prompted studies of
ETV-TP in assays using purified HIV RT and defined templates
[17,36]. These studies [17] confirmed the delayed mechanism of
ETV chain termination, shown previously in HBV [3,4], and
supported our modeling studies [3] which proposed the mecha-
nism to be similar to that of fixed conformation bases [16,37].
Furthermore, studies showed that LVDr YMDD-mutant HIV
displayed reduced recognition of ETV-TP [36]. It is interesting to
note that the potencies of ETV (EC50) and ETV-TP (Ki) are
significantly reduced against HIV [36,38] relative to HBV [5].
Thus YMDD-mutant HIV shows susceptibility levels near or
above the cytotoxic levels of ETV [17,38,39]. Therefore additional
substitutions analogous to the T184, S202 or M250 substitutions
in HIV might not be selected or provide increased resistance in the
HIV of HIV/HBV co-infected patients treated with ETV for
HBV.
The HBV ETVr changes at T184, S202 or M250 had little
effect on ETV susceptibility in the absence of LVDr changes [5]
and, among isolates from .1000 patients sequenced as part of our
resistance surveillance program [10,40] and unpublished), none of
the three ETVr-specific changes was found in HBV that lacked
LVDr substitutions. The present modeling experiments suggest the
basis for finding ETVr changes only in the context of LVDr HBV.
The M204 LVDr residue is critical to the stability of the YMDD
loop and the dNTP binding pocket. The ETVr changes can
further displace the position of the YMDD loop only after it has
been destabilized by the M204 change. Perhaps this is why only a
few changes to M204 are tolerated [14] while it appears that
several changes can be accommodated at positions of ETVr [6].
Indeed the variety of ETVr substitutions found in patients includes
T184A, C, F, G, I, L, M or S, S202C, G or I, and M250 I, L or V.
Not all of these substitutions result in significant reductions in ETV
phenotypic susceptibility or lead to virologic breakthrough [8].
Experiments suggest that this results from insufficient levels of
either resistance or replication capacity, or both, for some of the
substitutions [8]. In addition, we suggest that subtle steric or
dynamic changes in the ETV-binding site, or the conformation of
the active RT/ETV-TP/template structure, could affect levels of
resistance.
An unexpected finding was that there would be differences in
the mechanism of resistance between the T184 and S202
substitutions and those at position M250. The changes at T184
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YMDD loop and affecting the size of the ETV-TP binding pocket.
However, different substitutions can have effects both sterically, by
stably affecting the position of the YMDD loop and the pocket, or
dynamically, by interrupting the stabilizing H-bonding network
between the YMDD and the adjacent alpha helix. The larger
T184L and S202I substitutions are examples that sterically affect
the YMDD loop position. Substitutions T184G and S202G
however are examples where the major changes appear to involve
disruption of the stabilizing H-bonding network between T184
and S202.
Substitutions of M250 that result in ETVr, presumably within
the ‘primer grip’ portion of RT [18], are less straightforward to
explain mechanistically. While these changes also reduce the
binding of ETV-TP by HBV RT, modeling suggests they act
through contacts with Y203 or the primer strand of DNA. What
we have seen is that M250 substitutions are unique in that
resistance appears to reside primarily in minus strand DNA
synthesis, suggesting that contacts with the primer-template may
be involved in resistance. Indeed, during minus-strand synthesis,
when the template is RNA, resistance at M250 is more apparent
than when the template for synthesis is the narrower DNA
template of plus-strand synthesis. Consistent with this theory is the
finding that M250 substitutions with extended side chains,
tryptophan, tyrosine and phenylalanine, retain ETV susceptibility.
These residues likely can retain the positioning of the primer
template, while those with smaller side chains do not, resulting in
reduced ETV susceptibility [8].
There are still several unanswered issues concerning ETVr
HBV. Firstly, why so many different substitutions are found at
positions T184 and S202. Perhaps the basis lies in the fact that
resistance can result from two pathways, either sterically with large
residue substitutions, or dynamically by disrupting the H-bonding
network in the active site. The fact that the overlapping HB
surface antigen open reading frame is affected by changes at these
positions may serve to restrict the repertoire of residues from a
potentially larger list.
Additionally, genotypic HBV analysis of the patients with ETVr
emerging on therapy during 5 year surveillance[6] revealed that
89% of ETVr patients had substitutions at T184, S202 or both,
with 17% being a combination of the two. In contrast, only 11%
had substitutions at M250, alone (5.5%) or in combination with
those at T184 or S202 (5.5%). These results suggest that the M250
resistance substitution was much less common than those at T184
and S202, and even the combination of T184 and S202. This is
surprising when considering that T184 and S202 changes can
impact the sequence of the overlapping HBV surface antigen gene
while those at M250 do not, as well as the fact that the vast
majority of engineered changes at M250 resulted in phenotypic
resistance to ETV [8].
An additional unanswered issue is why ETVr substitutions
leading to virologic breakthrough occur only in LVDr HBV with
the M204V+L180M substitutions and not M204I HBV [10]. We
also have seen a very limited set of substitutions at T184 or M250
substitutions in viruses with the M204I LVDr change, and those
that occur in both LVDr types show higher levels of resistance in
the M204V+L180M background [7]. Our current hypothesis is
that interactions between residues at position 204 and those at
184, 202 or 250 are important for a functional HBV RT enzyme,
or perhaps that the ETVr substitutions further decrease the
replication capacity of the more impaired M204I virus to below
levels required to survive.
Finally, the impact of substitutions at residue I169 to ETVr
must also be explored. I169T substitutions were found in both
patients initially identified with ETVr [5] and various I169
substitutions have been seen in twelve of our other ETVr patients
[6]. In general, several residues at position 169 were observed,
including I169 L, M, T and S. In these patients, I169 substitutions
were only observed to emerge coincident with or after primary
ETVr substitutions at T184, S202 or M250, except in the case of a
single LVD-treated patient. I169 changes were not required for
virologic breakthrough or high level phenotypic resistance. I169
changes alone in LVDr HBV do not impart high level phenotypic
ETV resistance, whereas changes at T184, S202 and M250 can.
These observations are all consistent with the I169 substitution
being a secondary or ancillary substitution for ETVr, perhaps
fulfilling an adaptive change to compensate for replication
impairment imparted by the primary ETVr substitutions.
While the mechanistic interpretations of resistance for HIV
have been supported by structural data, no such data are available
for HBV. Thus only homology models of the HBV RT, based on
the HIV RT structure, have combined with genotypic and
phenotypic data to provide mechanistic insight into HBV
resistance. Consistent findings in the HBV model and HIV
structure (e.g. lamivudine resistance, [18]) support the reliability of
the HBV model, although it still lacks the validation of direct
structural data. This remains an important challenge in the field of
antiviral therapy for HBV.
Materials and Methods
Antiviral Compounds
ETV was prepared at BMS. The triphosphate form of ETV was
prepared by TriLink Biotechnologies, Inc. (San Diego, CA), Other
NRTIs and triphosphates were available from Moravek Biochem-
icals (Brea, CA) or TriLink.
Cells and Viruses
HepG2 human hepatoma cells (American Type Culture
Collection) were maintained as described [10]. The laboratory
clone of HBV was the genotype D ayw serotype clone kindly
provided by Dr. Steven Goff in the plasmid pCMV-HBV [41].
Plasmids expressing HBV RT with resistance substitutions were
prepared using QuikChangeH site-directed mutagenesis (Strata-
gene, LaJolla, CA).
In Vitro HBV Polymerase Assay
To provide the data in Tables 1 & 2, intracellular HBV
nucleocapsids were isolated from HBV transfected HepG2 cells and
used in endogenous polymerase assays (EPA) [42], exactly as
previously described in detail [5]. Essentially, clarified, detergent
and nuclease-treated HBV-transfected cell lysates werecentrifugally
sedimented through a 25% wt/vol sucrose cushion. Sedimented
nucleocapsids were used in polymerase reactions with [33P]-labeled
dNTPs and TCA-precipitable radioactivity was used as an
indication of the HBV polymerase activity, as described [5].
In order to increase the activity of the EPA reactions, we used
nucleocapsids from cells treated with phosphonoformic acid
(foscarnet, PFA; Sigma) during culture. PFA noncompetitively
inhibits the polymerase of all hepadnaviruses studied, as well as
other reverse-transcriptases and DNA polymerases (reviewed in
Oberg, 1989 [43]). PFA has been shown to inhibit elongation by
human HBV polymerase in vitro [19,44,45], and even HBV
polymerase expressed from recombinant insect cells [19,46] or in
cell-free systems [47]. PFA inhibits synthesis of all HBV DNA
forms and both strands of HBV DNA, but not priming, and has a
cell culture EC50 of approximately 5 mM for HBV [48].
Therefore, we used 1 mM PFA in cultures, a level that would
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but still enable sufficient synthesis to quantify nucleocapsids using
HBV real-time-PCR, as described [5].
The HBV polymerase dNTP Km values were determined from
similar assays where the concentration of dNTP was serially
diluted from 1000 nM to 0.3 nM. All other dNTPs were used at a
fixed concentration equal to the highest test dNTP concentration
with one-tenth of the TTP in the form of [a
33P] TTP (3000 Ci/
mmol; PerkinElmer, Boston, MA). The apparent Km values were
obtained from Lineweaver-Burke plots of the data generated by
GraphPad PRISM
TM software version 3.0 (San Diego, CA). The
Ki values were calculated using the Cheng-Prusoff equation:
Ki=IC 50/(1+[S]/Km) [49]. The enzyme concentration within
HBV nucleocapsid preparations was found by determining the
level of covalently-linked HBV DNA using quantitative real-time
PCR [9] and converting to genome equivalents [1 pg double
stranded HBV DNA=3610
5 genome equivalents [34]]. The
primers were positioned near the 59 end of minus strand DNA in
an attempt to measure all enzymatically active molecules.
HBV Cell Culture Susceptibility
HepG2 cell culture susceptibility assays were performed in cells
transfected with HBV expression plasmids and cultured in the
presence of a titration of antiviral compounds, as described in
detail elsewhere [7]. The levels of replicated, released HBV virions
was measured at day five through immunocapture of detergent
released nucleocapsids with anti-HBV core Ab and quantification
of encapsidated HBV DNA [5]. Data were plotted as percent
inhibition and EC50 values calculated as the drug concentration
where 50% inhibition of extracellular HBV occurred.
Metabolic Labeling of HBV DNA in Culture
The results in Figure 1 were derived from intracellular labeling
of HBV DNA with [3H]-ETV, and quantitating relative to total
HBV DNA. Cells were transfected and grown for two days in
defined media (OptiMEM I; Invitrogen, Carlsbad, CA) containing
either 100 nM [
3H]-ETV (7.3 Ci/mmol) or [
3H]-thymidine
(80.2 Ci/mmol; PerkinElmer). Intracellular HBV nucleocapsids
were isolated by sedimentation through sucrose, as described
above. [
3H]-ETV-labeled DNA was from cultures with [
3H]-ETV.
Total HBV DNA was determined on the same samples using
quantitative real-time-PCR, as described [5]. An additional
control for total HBV DNA used nucleocapsids isolated from
parallel cultures labeled with [
3H]-thymidine. Both methods gave
similar results. Radiolabeled HBV DNA was quantified by mixing
nucleocapsids with an equal volume of 20% ice-cold trichlor-
oacetic acid, collected by vacuum filtration on GF/B plates
(PerkinElmer) and analyzed for [
3H] by scintillation counting of
acid-insoluble material.
HBV Cell Culture Strand-Specific EC50 Determination
Cell culture susceptibility assays were performed as above,
except that extracted HBV DNA was blotted onto nylon
membranes and hybridized with strand-specific riboprobes
generated as described [4] except the riboprobes were fluoresce-
in-labeled and a chemiluminescent signal was generated using an
alkaline phosphatase-conjugated anti-fluorescein antibody as
specified in the manufacturer’s instructions (Amersham; Piscat-
away, NJ). Both sense and antisense riboprobes, which were
1168 bp in length and complementary to Xba I (nt 2143) to XhoI
(nt 129) were generated by in vitro transcription (T3 and T7-
Maxiscript; Ambion, TX). The double-stranded DNA probe used
for comparison was the unit length 3.2-kbp HBV genotype D
genome fragment.
Homology Models of HBV-RT/DNA Complex
A homology model for the wildtype HBV-RT/DNA/dGTP
complex was developed based on the sequence alignment between
HBV RT and HIV RT [18] and the HIV-RT/DNA x-ray
structure (1RTD.pdb) [50] using the Protein Design Module in
Quanta (QUANTA Modeling Environment release 2000. Accelrys
Software Inc., San Diego, CA.). Additional HBV-RT homology
models were constructed with the LVD (M204V+L180M) and
adefovir (A181T/V and N236T) resistance substitutions, and the
ETVr signature substitutions T184G & S202I, or M250V were
constructed on the LVDr (M204V+L180M) model. An additional
model of the M250V was also constructed in WT HBV RT. The
two HBV RT active site Magnesium ions and relative positions
were homology built from the 1RTD.pdb structure. Note: as
observed in our earlier study an extensive hydrogen-bonding
network exists between HBV-RT and the tri-phosphate moiety
[see figure 1B from [3]] of a NTP or equivalent inhibitor form.
The relative position of the tri-phosphate moiety to the YMDD
loop is further defined by the Mg ion bridge between the tri-
phosphate moiety and D83/D205 which positions and anchors
D205 of the YMDD loop and the tri-phosphate moiety of the
NTP/inhibitor into the NTP binding site. Modeling NTP’s or
inhibitor’s bound in the presence of the Mg ion bridge produces
models with YMDD loop and NTP’s/inhibitor’s tri-phosphate
conformations that were in close agreement with those observed in
HIV RT x-ray structures, however, when modeled in the absence
of the Mg ion bridge the structures are noticeably distorted (data
not shown), highlighting the need to include the Mg ions in the
model.
Using the DNA from the 1RTD.pdb structure as the template,
different HBV RT models were constructed including the DNA
[d(GCXCCGGCGCTCG)-d(CGAGCGCCGG)] and RNA/DNA
[(GCXCCGGCGCTCG)-d(CGAGCGCCGG)] to model the four
DNA base types and the nucleotide HBV-RT inhibitors (ETV
(X=C), LVD (X=G), adefovir (X=T), and telbivudine (X=A))
bound in the dNTP binding site. Two additional RNA/DNA
models were constructed with ETV modeled at the 39(+1), and
39(+2) positions of the newly synthesized DNA strand. The region
around the WT HBV RT dNTP binding site was equilibrated, with
dGTP bound in the dNTP binding site, by running a restrained 2
nanosecond molecular dynamics simulation.
Modeling studies were conducted with Quanta (QUANTA
Modeling Environment release 2000. Accelrys Software Inc., San
Diego, CA.) and CHARMM [51] running on a Silicon Graphics
computer. The modeling figures presented were produced using
DS ViewerPro 6.0 (Accelrys Software Inc., San Diego, CA.). The
CHARMM parameters [52] were used for all calculation carried
out within the QUANTA program while the CHARMM22 [53]
and CHARMM27 parameters [54] were used for the molecular
dynamics simulations. Switching functions were used in both
energy minimization and molecular dynamics for the nonbonded,
van der Waals and electrostatic interactions between 8 A ˚–10 A ˚
with an 12 A ˚ cutoff [55,56]. The GBORN module [57] within
CHARMM was used to calculate the Generalized Born salvation
energy and forces. The Verlet algorithm [58] was used to calculate
the classical equations of motion for the atoms and the X-H bonds
were fixed using the SHAKE algorithm [59] during MD. The
following restraints were applied during all calculations: All
residues with one or more atoms within 13 A ˚ of the dGTP bound
in the dNTP site were not constrained; the residues within the
13 A ˚–20 A ˚ zone from dGTP were positionally constrained with a
5 kcal harmonic tether, while all residues outside the 20 A ˚ zone
were tethered with a 50 kcal harmonic constraint. Each system
was minimized with 200 steps of steepest descents followed by 500
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following molecular dynamics protocol was applied to each
system: In a 1.5 pico-seconds (psec) heating phase the temperature
was raised to 300 K in steps of 10 K over 0.05 psec blocks. The
MD velocities were reassigned after every step based on the
Gaussian approximation to the Maxwell Boltzmann distribution.
This was followed by an equilibration phase in which the velocities
were allowed to rescale over the next 18.5 psec in steps of
0.25 psec to stabilize the system within a 30065 K window. The
production phase continued for another 2 nsec where the
velocities were allowed to rescale every 0.5 psec to keep the
system within a 300610 K window.
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